IGF-1 LR3 Research for Muscle Wasting
An evidence-based overview of research examining IGF-1 LR3 in the context of muscle wasting. This page synthesizes findings from peer-reviewed literature.
Research Summary
IGF-1 signaling inhibits FOXO transcription factors that drive muscle atrophy. In animal models of muscle wasting (including muscular dystrophy), IGF-1 LR3 improved muscle function. Clinical trials for wasting conditions have used native IGF-1, not the LR3 variant.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Muscle Wasting
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. IGF-1 LR3 has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.